ClinicalTrials.gg
CompletedNCT07530289Updated Jun 15, 2026

A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)

A Phase 1 interventional study of Atorvastatin and Metformin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Researchers want to learn about ulonivirine when given with atorvastatin and metformin in healthy people. The goal of this study is to compare the amount of atorvastatin and metformin in a person's body over time when given with and without ulonivirine.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has (BMI) 18.0 and ≤ 32.0 kg/m\^2
  • Is medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, and (ECG)

Exclusion criteria

Exclusion Criteria:

  • Has history of cancer ()
  • Positive results for (HIV), surface antigen (HBsAg), or virus (HCV)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Atorvastatin + metformin + ulonivirine

    In Period 1, participants will receive atorvastatin and metformin. In Period 2, participants will receive atorvastatin, metformin, and ulonivirine.

    Drug: Atorvastatin · Drug: Metformin · Drug: Ulonivirine

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Atorvastatin

    Blood samples will be collected at multiple time points to determine the AUC0-inf of atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  2. AUC0-inf of Metformin

    Blood samples will be collected at multiple time points to determine the AUC0-inf of metformin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

Secondary outcomes

  1. Area Under the Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of Atorvastatin

    Blood samples will be collected at multiple time points to determine the AUC0-last of atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  2. Maximum Plasma Concentration (Cmax) of Atorvastatin

    Blood samples will be collected at multiple time points to determine the Cmax of atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  3. Plasma Concentration at 24 Hours (C24) of Atorvastatin

    Blood samples will be collected to estimate the C24 of atorvastatin

    Time frame: 24 hours post-dose

  4. Time to Maximum Plasma Concentration (Tmax) of Atorvastatin

    Blood samples will be collected at multiple time points to estimate the Tmax of atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  5. Apparent Terminal Half-life (t1/2) of Atorvastatin

    Blood samples will be collected at multiple time points to estimate the t1/2 of atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  6. AUC0-last of Atorvastatin Metabolite (2-OH Atorvastatin)

    Blood samples will be collected at multiple time points to determine the AUC0-last of 2-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  7. AUC0-inf of 2-OH Atorvastatin

    Blood samples will be collected at multiple time points to determine the AUC0-inf of 2-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  8. Cmax of 2-OH Atorvastatin

    Blood samples will be collected at multiple time points to determine the Cmax of 2-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  9. C24 of 2-OH Atorvastatin

    Blood samples will be collected to estimate the C24 of 2-OH atorvastatin

    Time frame: 24 hours post-dose

  10. Tmax of 2-OH Atorvastatin

    Blood samples will be collected at multiple time points to estimate the Tmax of 2-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  11. t1/2 of 2-OH Atorvastatin

    Blood samples will be collected at multiple time points to estimate the t1/2 of 2-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  12. AUC0-last of Atorvastatin Metabolite (4-OH Atorvastatin)

    Blood samples will be collected at multiple time points to determine the AUC0-last of 4-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  13. AUC0-inf of 4-OH Atorvastatin

    Blood samples will be collected at multiple time points to determine the AUC0-inf of 4-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  14. Cmax of 4-OH Atorvastatin

    Blood samples will be collected at multiple time points to determine the Cmax of 4-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  15. C24 of 4-OH Atorvastatin

    Blood samples will be collected to estimate the C24 of 4-OH atorvastatin

    Time frame: 24 hours post-dose

  16. Tmax of 4-OH Atorvastatin

    Blood samples will be collected at multiple time points to estimate the Tmax of 4-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  17. t1/2 of 4-OH Atorvastatin

    Blood samples will be collected at multiple time points to estimate the t1/2 of 4-OH atorvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  18. AUC0-last of Metformin

    Blood samples will be collected at multiple time points to determine the AUC0-last of metformin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  19. Cmax of Metformin

    Blood samples will be collected at multiple time points to determine the Cmax of metformin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  20. C24 of Metformin

    Blood samples will be collected to estimate the C24 of metformin

    Time frame: 24 hours post-dose

  21. Tmax of Metformin

    Blood samples will be collected at multiple time points to estimate the Tmax of metformin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  22. t1/2 of Metformin

    Blood samples will be collected at multiple time points to estimate the t1/2 of metformin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  23. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 21 days after first dose

  24. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 7 days after first dose

07

Study locations

1 site
  • Celerion ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in May 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 15, 2026
StartActual
Apr 29, 2026
Primary completionActual
May 23, 2026
CompletionActual
Jun 3, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530289
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Apr 29, 2026
Primary completion
May 23, 2026
Completion
Jun 3, 2026
Last update
Jun 15, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Metformin · Ulonivirine

Start the discussion